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Survival benefits of surgical resection in recurrent 
cholangiocarcinoma
Sun Choon Song, Jin Seok Heo, Dong Wook Choi, Seong Ho Choi, Woo Seok Kim, Min Jung Kim
Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
Purpose: Attempt to identify the beneficial effects associated with surgical procedures on survival outcome of patients with 
recurrent cholangiocarcinoma. Methods: 921 patients diagnosed with cholangiocarcinoma underwent surgical resection 
with curative intent in a single institute during the last 15 years. Patients with recurrent disease were divided into two groups 
according to whether surgical procedures were performed for the treatment of recurrence. Clinicopathologic variables, rang-
es of survival based on sites of recurrence, and types of treatment were analyzed retrospectively. Results: The median fol-
low-up period was 21.8 months and 316 (34.3%) patients had recurrence. 27 (group A) patients with recurrent disease were 
treated surgically and 289 patients (group B) were not treated. Liver resection, metastasectomy, pancreaticoduodenectomy, 
partial pancreatectomy, and regional lymph node dissection were performed on the patients in group A. The overall survival 
rate was statistically higher in group A (P = 0.001). Among the surgical procedures, resection of locoregional recurrences 
(except liver) in abdominal cavity (4.0 to 101.8 months vs. 0.6 to 71.6 months) and metastasectomy of abdominal or chest wall 
(3.5 to 18.9 months vs. 1.9 to 2.2 months) showed remarkable differences with respect to the range of survival. Conclusion: 
Better survival outcomes can be expected by performing surgical resection of locoregional recurrences (except liver) in ab-
dominal cavity and abdominal or chest wall metastatic lesions in recurrent cholangiocarcinoma. 
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INTRODUCTION
Cholangiocarcinoma is the second most common pri-
mary hepatobiliary malignancy originating from the epi-
thelium of the intrahepatic, perihilar, or extrahepatic bile 
ducts, with the frequencies of 5 to 30%, 40 to 50%, and 20 to 
30%, respectively [1-5]. The incidence of intrahepatic chol-
angiocarcinoma is increasing worldwide, especially in 
Asia, while the incidence of extrahepatic cholangiocar-
cinoma is somewhat stable or declining [6-11]. Surgical re-
section remains the only curative treatment option for 
cholangiocarcinoma, but most patients are far advanced at 
the time of presentation, which leads to a poor survival 
outcome [12-16]. In addition, spreading widely through 
bile ductules and extensive invasion to adjacent organs, 
cholangiocarcinoma has frequent locoregional or distant 
recurrences via lymphatic chains or hematogenous meta-
stasis [4,5,12,17,18]. Kobayashi et al. [19] reported distant Sun Choon Song, et al.
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metastases were more common than locoregional recur-
rence after R0 resection in patients with perihilar cholan-
giocarcinoma.
The 5-year overall survival rate after surgical resection 
of cholangiocarinoma is reported to be 5 to 40%, and the 
median overall survival time and median recurrence-free 
survival time is 27 to 33 and 9 to 27 months, respectively 
[6-8,10,13,15,18-20]. Many published series have reported 
the risk factors for poor survival and recurrence; peri-
neural invasion via lymphatic pathway and the proximity 
to the peripheral nerve plexus, presence of lymph node 
metastasis, poor differentiation, higher T stage, positive 
surgical resection margin and high level of carbohydrate 
antigen (CA) 19-9 [12,15,17,19-21]. The recurrence sites 
vary from local or locoregional recurrence in abdominal 
cavity to distance metastasis including abdominal or chest 
wall, skeletal muscles, lung, bone or brain [1,6,5,22,23]. 
Repeated hepatic resection for large, resectable tumors 
or radiofrequency ablation (RFA) for several small nod-
ules have demonstrated their effectiveness on survival for 
the treatment of recurrent intrahepatic cholangiocar-
cinoma in some series [17,18,24]. 
However, there is no large-scale series to verify benefi-
cial effects in terms of survival through surgical treat-
ments including other types of recurrent cholangiocar-
cinomas. Thus, we attempted to identify whether or not 
there is a survival benefit to patients with recurrent chol-
angiocarcinoma who had undergone surgical resection 
with curative intent according to the recurrent sites and 
the types of resection. 
METHODS
Study patients
Nine hundred forty-nine patients who underwent sur-
gical treatment for cholangiocarcinoma in a single in-
stitute between May 1995 and July 2010 were reviewed ret-
rospectively based on electronic medical records with 
pathologic reports. They proved to be primary adeno-
carcinomas pathologically arising from the bile duct epi-
thelium. With the exception of 28 patients who had pallia-
tive resection, 921 patients underwent curative-intent sur-
gical resection (R0 = 830, R1 = 91). 
Cholangiocarcinoma was classified according to the tu-
mor location according to preoperative radiologic and fi-
nal pathologic findings, which included intrahepatic (n = 
226), perihilar (n = 222), and extrahepatic (n = 474). Cholan-
giocarcinoma of gallbladder was not included in this 
series. 74, 78 and 164 patients had recurrent diseases dur-
ing the study period, respectively. These 316 patients were 
divided into the following 2 groups: patients who under-
went surgical resection for recurrence (group A) and pa-
tients who were not treated (group B).
Initial procedures and managements
To the patients with intrahepatic cholangiocarcinomas, 
anatomic liver resection, including segmentectomy, hemi- 
hepatectomy, extended hemi-hepatectomy, or tri-sectio-
nectomy (with or without caudate lobectomy) were pri-
marily considered. Wedge resection was also considered 
for small tumors located at the liver dome. Variable proce-
dures, such as major hepatectomy with bile duct resection, 
hepatopancreaticoduodenectomy, pancreaticoduodenec-
tomy, segmental bile duct resection, or liver transplan-
tation were performed for perihilar cholangiocarcinoma 
according to Bismuth-Corlette type, tumor location and 
degree of infiltration. Finally, segmental bile duct re-
section or pancreaticoduodenectomy was primarily con-
sidered for extrahepatic cholangiocarcinoma based on the 
location of the tumor (upper-, middle-, and lower-third). 
Hepatopancreaticoduodenectomy was applied to the pa-
tient with widespread cholangiocarcinoma and suspected 
invasion to the hepatoduodenal ligaments considering the 
medical condition of the patient.
Routine frozen-sectional biopsy of ductal resectional 
margin was carried out to confirm microscopic extension 
during surgery. When the proximal or distal margin was 
proved to be tumor positive, additional resection of bile or 
hepatic ducts was performed. The regional lymph nodes 
in the hepatoduodenal ligament, peri-pancreatic, celiac, 
and along the common hepatic artery were dissected, but 
the degree of lymph node dissection was determined by 
the attending surgeon. If the pathologic evaluation re-
vealed lymph node metastasis or positive resection mar-
gins, the patient was recommended to receive adjuvant Surgical treatments for recurrent cholangiocarcinoma
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Group A (n = 27) Group B (n = 289) P-value
Gender (M:F), n (%) 14 (51.9):13 (48.1) 185 (93.0):104 (88.9) 0.218
Age, mean (range)  58.3 (45-69)   60.4 (31-79) 0.255
Tumor location,
  n (%)
0.720
Intrahepatic  5 (18.5)   69 (23.9)
Perihilar       9 (33.3)   69 (23.9)
Extrahepatic 13 (48.1) 151 (52.2)
Differentiation,
  n (%)
0.889
Well  2 (8.3)   33 (12.4)
Moderate 13  (54.2) 144  (54.1)
Poorly    9 (37.5)   87 (32.7)
Undifferentiated             0 (0)   2 (0.8)
Tumor staging
 (AJCC 7th), n (%)
0.280
I (IA, IB)   7 (30.4)   36 (14.8)
II (IIA, IIB) 12 (52.2) 134 (55.1)
III (IIIA, IIIB)   3 (13.0)   48 (19.8)
IV (IVA, IVB) 1 (4.3)   25 (10.3)
Radicality, n (%) 1.000
R0 25 (92.6) 258 (89.3)
R1 2 (7.4)   31 (10.7)
Adjuvant CCRT,
 n (%)
22 (81.5) 172 (59.5) 0.037
Time-to-recurrence 
 (mo), median  (range)
15.0 (1.3-133.4) 10.1 (1.2-120.3) 0.118
AJCC, American Joint Committee on Cancer; CCRT, concurrent 
chemoradiotherapy.
Table 1. Demographics and clinicopathologic variables 
treatment. 5-fluorouracil-based chemotherapy and radio-
therapy (44-54 Gy) were generally applied, although there 
were differences in the dose and treatment period accord-
ing to the individual.
Types of treatment for recurrence
　Patients were routinely followed in the outpatient de-
partment with CA 19-9 levels and abdominal con-
trast-enhanced computed tomography (CT) every 3 to 6 
months. Recurrence was highly suspected when the level 
of serum CA 19-9 increased, and confirmed with CT with 
or without 18F-fluorodeoxyglucose positron emission to-
mography by experienced radiologists. It was classified as 
one of followings; intrahepatic recurrence, locoregional 
recurrence except liver, distant metastasis.
The inclusion criteria for RFA generally followed the in-
dications for hepatocellular carcinoma; ＜3 tumor lesions 
with a maximum diameter ＜3 cm, single nodular lesions 
with a maximum diameter ＜5 cm, no major vessel or bile 
duct involvement, and no uncorrectable coagulopathy 
[25]. The technical effectiveness was verified with a CT af-
ter 1 month with no residual unablated tumors.
Further hepatic resection was considered according to 
the anatomic location, size, and number of lesions when 
RFA could not be performed. Metastasectomy was consid-
ered for metastatic lesions of the abdominal wall, chest 
wall, peritoneum, and solitary pulmonary nodules. 
Pylorus-preserving pancreaticoduodenectomy or Whip-
ple’s procedure was performed to treat locoregional re-
currence after segmental bile duct resection for extra-
hepatic cholangiocarcinoma.
Statistical analysis
A Student’s t test (two-tailed) and χ
2 test or Fisher’s ex-
act test were used to analyze continuous or categorical var-
iables, respectively. Overall survival was calculated using 
the Kaplan-Meier method and differences in survival were 
determined using the log-rank test. Prognostic factors on 
overall survival were indentified using multivariate Cox 
proportional hazards models. Statistical calculations were 
performed using SPSS ver. 16.0 (SPSS Inc., Chicago, IL, 
USA). P-values ＜ 0.05 were considered statistically 
significant.
RESULTS
Demographics
The median follow-up period was 21.8 months (range, 
1.8 to 153.0 months) and the number of patients was 27 and 
289 in group A and B, respectively. There were no stat-
istical differences in gender, age and pre-operative carci-
noembryonic antigen and CA 19-9 levels. In addition, tu-
mor size, location, differentiation, radicality, the ratio of 
lymph node metastasis, tumor staging and time-to-re-
currence did not have significant differences, except the 
rate of patients receiving adjuvant concurrent chemo-
radiotherapy, which was shown to be statistically higher 
in group A (P = 0.037, Table 1). 
Recurrence after surgical resection
5, 9 and 13 patients underwent surgical treatment for re-Sun Choon Song, et al.
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Types 
Recurrent 
rates (%)
Surgical 
resection 
(n)
RFA 
treatment 
(n)
Intrahepatic    74/226 (32.7)   5 3
Perihilar    78/222 (35.1)   9 1
Extrahepatic 
Segmental bile duct 
  resection
  33/120 (27.5)   8 1
Pancreaticoduodenectomy 131/354 (37.0)   5 2
Total 316/921 (34.3) 27 7
RFA, Radiofrequency ablation.
Table 2. Recurrent rates according to the tumor types after R0, R1 
resection
Treatment (n) Comments
Liver  resection  (7)  Right hemi-hepatectomy (1), Left hemi-hepatectomy (1), Wedge resection (1), Sectionectomy (2), 
Tumorectomy (2
a)) 
Metastasectomy (10) Chest wall (3), Abdominal wall (2), Peritoneum (2), VATs-WR of lung (3
b)) 
Pancreaticoduodenectomy (8)  Whipple’s procedure (4), PPPD (4) 
Partial pancreatectomy (1)  This patient previously underwent right trisegmentectomy due to hilar cholangiocarcinoma. After 14 
months, he underwent intra-operative RFA due to second recurrence at hepatic resection margin
Regional lymph node dissection (1) Intrahepatic cholangiocarcinoma with lymph node metastasis
RFA (7) All were percutaneous RFA
VATs-WR, video-assisted thoracic surgery-wedge resection, PPPD, pylorus-preserving pancreaticoduodenectomy, RFA, radiofrequency 
ablation.
a)One patient underwent RFA after 2 months due to second hepatic recurrence. 
b)One patient underwent hepatic tumorectomy after 1 month 
due to second hepatic recurrence. 
Table 3. Treatment types for recurrence
Recurrent sites
Time-to-recurrence 
(treatment case/total)
Within 1 yr  From 1 to 2 yr  Above 2 yr 
Liver, solitary  7/52   1/21    1/10
Liver, multiple  0/14  0/3  0/0 
Locoregional except 
  liver
 3/48    3/40   7/30
Lung or pleura  1/10  1/5  0/5 
Abdominal or chest wall 3/5  1/1  1/1 
Peritoneum, solitary 1/1  1/1  0/0 
Peritoneal seeding  0/36  0/5  0/6 
Bone 0/4 0/0 0/1 
Brain 0/1 0/1 0/0 
Supraclavicular lymph 
  nodes
0/1 0/1 0/0 
Multiple sites 0/8  1/2  2/3 
Total  15/180   8/80 11/56
Table 4. Patterns of recurrence according to the recurrent sites and 
time-to-recurrence
current disease in the case of intrahepatic, perihilar, and 
extrahepatic cholangiocarcinoma, respectively (Table 2). 
The recurrent rate was highest after pancreaticoduo-
denectomy (37.0%) for extrahepatic cholangiocarcinoma. 
The recurrent sites were as follows; solitary (n = 83) or mul-
tiple (n = 17) hepatic recurrence, locoregional recurrence 
except liver (n = 118), peritoneal seeding (n = 49), lung or 
pleura (n = 20), abdominal or chest wall (n = 7), bone (n = 5), 
brain (n = 2), supraclavicular lymph node (n = 2) and multi-
ple site recurrence (n = 13). 
Hepatic resection or RFA was performed for liver 
metastasis. Pancreaticoduodenectomy, partial pancrea-
tectomy, and regional lymph node dissection were per-
formed for locoregional recurrent lesions. Metastasecto-
my was performed for recurrent masses in the abdominal 
or chest wall, lung or pleura, and peritoneal solitary 
metastasis. Partial pancreatectomy was performed on one 
patient who had a locoregional recurrence in the pancreas 
after right tri-segmentectomy for type IIIA hilar cholan-
giocarcinoma. One patient had a recurrence in regional 
lymph nodes 17.4 months after left lateral sectionectomy 
for intrahepatic cholangiocarcinoma located at segments 
II and III (Table 3). In the current study, we did not perform 
surgical resection or RFA for multiple hepatic metastatic 
lesions, and surgical procedures for peritoneal seeding, 
supraclavicular lymph node and bone or brain metastasis. 
180, 80 and 56 patients had recurrence within 1 year, 
from 1 to 2 years, and above 2 years, respectively. During 
these periods, various treatments for recurrence were per-Surgical treatments for recurrent cholangiocarcinoma
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Fig. 1. Overall survival rate after recurrence according to surgical 
treatment and concurrent chemoradiotherapy (CCRT) for recur-
rent cholangiocarcinoma (group A; patients treated surgically for 
recurrence, group B; patients not treated, P-value between the two 
groups = 0.001).
Group A (n = 27) Group B (n = 289)
Recurrent sites (n) Ranges of survival (mo) Recurrent sites (n) Ranges of survival (mo)
Liver, solitary (4)   6.8-58.5 Liver, solitary (79)   1.0-89.1
Locoregional except liver (12)     4.0-101.8 Liver, multiple (17)   0.8-30.3
Lung or pleura (2) 4.9-6.3 Locoregional except liver (106)   0.6-71.6
Abdominal or chest wall (5)   3.5-18.9 Lung or pleura (18)   1.5-38.7
Peritoneum, solitary (2)   1.7-20.1 Bone (5)   2.2-17.2
Multiple site (2)   9.8-22.4 Brain (2) 4.6-7.5
Abdominal or chest wall (2) 1.9-2.2
Peritoneal seeding (47)   0.5-35.5
Supraclavicular lymph node (2) 14.6-21.8
Multiple sites (11)   1.4-32.5
Table 5. Recurrent sites and ranges of survival after recurrence
Variables
Hazard 
ratio
95% 
confidence 
interval
P-value
No surgical resection 2.308 1.112-4.787 0.025
R1 resection 1.576 1.003-2.476 0.049
Not performed adjuvant CCRT 1.140 0.826-1.573 0.426
Lymph node metastasis 0.863 0.628-1.187 0.366
CCRT, concurrent chemoradiotherapy.
Table 6. Multivariate analysis of prognostic factors on overall 
survival after recurrence
formed to 9.3%, 10.0% and 19.6% of the recurrent patients, 
respectively (Table 4). 
Overall survival and range of survival after re-
currence
The median times to recurrence were 15.0 and 10.1 
months in group A and B, respectively (P = 0.118). The me-
dian times from recurrence to surgical treatment for re-
current disease in group A was 27 days (range, 14 to 182 
days). The median survival times after recurrence were 
18.9 months (range, 1.7 to 101.8 months) and 7.7 months 
(range, 0.5 to 89.1 months) in group A and B, respectively. 
The cumulative overall survival rate after recurrence was 
significantly higher in group A than group B (P = 0.001, 
Fig. 1). The additional chemoradiotherapy did not show 
significant survival benefits in either group. The beneficial 
effect of surgical treatment for recurrent disease with re-
spect to the ranges of survival was remarkable in the case 
of locoregional recurrence except liver and abdominal or 
chest wall metastasis (Table 5). Surgical resection for re-
current cholangiocarcinoma was identified as an in-
dependent prognostic factor on overall survival according 
to multivariate analysis (HR = 2.308, P = 0.025) (Table 6). 
DISCUSSION
The long-term survival outcomes of patients who un-
dergo surgical treatment for cholangiocarcinoma is still 
disappointing, although there have been recent advances 
in imaging modalities, peri-operative treatment, and sur-
gical techniques. Additionally, because of the advanced 
stage at presentation, inadequate identification of anatom-
ic location, and/or poor medical conditions, surgical re-Sun Choon Song, et al.
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section is often non-curative [10]. To this end, therapeutic 
strategies for advanced or metastatic cholangiocarcinoma 
have been developed, such as systemic chemotherapy, 
brachytherapy, photodynamic therapy and hepatic-ar-
terial embolization or cryoablation [7,10,19,26]. However, 
most have limited roles in representing satisfactory out-
comes on survival.
It is reported that liver and abdominal lymph nodes 
around the hepatoduodenal ligament, periportal, com-
mon hepatic artery, and posterior pancreatoduodenal 
areas are common sites of recurrence in patients with chol-
angiocarcinoma [5,19,27,28]. Occasionally, distant lymph 
nodes in the posterior mediastinum or supraclavicular 
area can be involved. These findings have commonly been 
accepted to reflect disease progression and are associated 
with a poor prognosis. 
Repeated liver resection in intrahepatic cholangio-
carcinoma, repeated RFA, or a combination for locore-
gional recurrent tumor have been reported to be effective 
with respect to survival in highly selected patients 
[9,17,18,25]. However, our study extended the concept of 
repeated resection beyond the liver to extrahepatic in-
tra-abdominal locoregional recurrences, abdominal or 
chest wall and lung or pleura. In addition to performing 
repeated hepatectomy or RFA for recurrent hepatic le-
sions, resection of recurrences in the abdominal cavity and 
abdominal or chest wall were attempted. In our experi-
ence, there were two of five cases showing positive re-
section margins after metastasectomy of the abdominal 
wall. Second recurrences occurred in these two patients, so 
they underwent repeated resection around the previous 
area of resection. Thus, wider excision must be considered 
during metastasectomy of the abdominal or chest wall, 
and mesh could be useful for covering large fascial defects 
in these cases.
In this series, the recurrence rate of cholangiocarcinoma 
showed 34.3%, and about 57% of recurrence occurred 
within 1 year. However, only 8.3% of patients with re-
currence were treated surgically in this period, while 
10.0% and 19.6% of patients were treated from 1 to 2 years 
and above 2 years, respectively. Thus, early surgical re-
section should be considered to acquire greater survival 
benefits. 
There are some drawbacks in this retrospective study. 
First, differences in the clinical course and pathogenesis 
among the three types of cholangiocarcinoma may exist. 
But it was reported that there were no significant differ-
ences in clinical presentation, disease stage and survival 
between intra- and extra-hepatic cholangiocarcinoma [6]. 
Second, a relatively smaller incidence of recurrence than 
in previous studies was identified. It might be influenced 
not by the development of the palliative treatment op-
tions, but also missed patients who were previously treat-
ed surgically. In fact, patients with cholangiocarcinoma 
have been increasing recently who were treated surgically 
or with RFA. Therefore, further follow-up studies for these 
patients are warranted to understand tumor biology and 
diverse patterns of tumor recurrence to make up for these 
limitations. Francis et al. [9] and Zhang et al. [4] in-
troduced regulation of cholangiocarcinoma from a bio-
logic point of view. Their reviews suggested that genetic 
hypermethylation, interleukin-6, growth factors, gastro-
intestinal hormones, neuroregulatory molecules, angio-
genesis, or E-cadherin-mediated cell-to-cell adhesion ex-
pressed by the Slug gene are related to growth or invasive-
n e s s  o f  t h e  t u m o r .  T h i r d ,  a l t h o u g h  m o s t  o f  t h e  c l i n -
icopathologic characteristics were similar in our two 
groups, the rate of patients who underwent adjuvant 
CCRT was higher in group A. This selection bias could be 
an interference factor in drawing our conclusion. Finally, 
overall survival has room for modification because the re-
currence patterns between the two groups were not 
similar. Thus, further prospective controlled study is 
needed to overcome this limitation.  
In conclusion, according to this large-series study in a 
single center, we have to consider surgical procedures to 
resectable recurrent lesions to prolong survival in patients 
with recurrent cholangiocarcinoma. Moreover, adjuvant 
chemoradiotherapy alone could not acquire a meaningful 
beneficial outcome on survival without resection of re-
current lesions. Although this series did not confirm any 
beneficial effect of surgical procedures to recurrent masses 
in the liver, lung, pleura, or multiple sites on survival, sur-
gical resection of locoregional recurrence in the abdominal 
cavity and of the abdominal or chest wall metastatic le-
sions showed remarkable benefits in terms of range of Surgical treatments for recurrent cholangiocarcinoma
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survival. This consideration might help to determine pat-
terns of recurrence and adequate therapeutic options for 
recurrent cholangiocarcinoma.
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